Sector News

EU panel backs slew of new drugs and uses, boosting Lilly, AZ, Novartis, Gilead and more

September 26, 2014
Life sciences
When Europe’s drug approval gatekeepers meet, they often tick off recommendations for some key Big Pharma products. This week, the Committee for Medicinal Products for Human Use backed a whopping 15 new meds and 3 new indications.
 
That’s more than one-quarter of the approvals they’ve issued this year, the CHMP helpfully pointed out in its wrap-up of decisions. Predictably, the pharma press releases went flying. Here are some of the highlights. You can find the entire list here.
 
– Eli Lilly got a double dose of good news: The committee backed Cyramza (ramucirumab), its star oncology prospect, for an orphan use in gastric cancer. It was approved by the FDA for the same use in April, and, armed with new data released earlier this month, Lilly plans to seek FDA’s blessing for colon cancer early next year.
 
– Lilly also won CHMP’s blessing for Trulicity (dulaglutide), its diabetes treatment that’s ready to compete head-to-head in the GLP-1 market with Novo Nordisk’s Victoza. As a long-acting injection, Trulicity has convenience on its side, and Lilly is hoping to turn that advantage into blockbuster sales. 
 
– Gilead Sciences nabbed CHMP backing for its new hepatitis C combination pill Harvoni (sofosbuvir plus ledipasvir). Up for an FDA decision next month, Harvoni is expected to follow in the footsteps of Sovaldi (sofosbuvir on its own), churning out sales by the billion on a price of almost $100,000 per course. 
 
– AstraZeneca managed a double win, too. Its new constipation drug for patients using opioid painkillers, Moventig, got the committee’s thumbs-up. The brand-new med–approved by FDA just last week under the brand name Movantik–is the first in a round of new drugs for the condition.
 
– AstraZeneca also will benefit from the CHMP’s recommendation on Brimica Genuair (aclidinium bromide plus formoterol fumarate), filed by Spain’s Almirall, to treat chronic obstructive pulmonary disease (COPD). AZ recently agreed to buy a portfolio of respiratory drugs from Almirall, including Brimica Genuair. It’s part of AZ’s efforts to rebuild a respiratory franchise after rivals to its blockbuster Symbicort erode sales. 
 
– Boehringer Ingelheim picked up an approval in oncology. Vargatef (nintedanib) won the CHMP green light as a treatment for non-small cell lung cancer. It’s not yet approved by the FDA, but the agency gave it the coveted “breakthrough” designation to speed it on its way to a decision for a blockbuster-potential use, to treat idiopathic pulmonary fibrosis. 
 
– Teva Pharmaceutical Industries got CHMP’s backing for a copycat version of AstraZeneca’s Symbicort, to treat COPD and asthma. The drug itself–budesonide plus formoterol–won a recommendation. And key to its launch, its delivery device did, too. So, Vylaer Spiromax could soon be a go. 
 
We’ll leave you to check out the CHMP’s release for its opinions on broader use of Novartis’ Cushing’s disease drug Signifor, AstraZeneca’s lung cancer drug Iressa and Johnson & Johnson’s antiviral Prezista.
 
By Tracy Staton
 

comments closed

Related News

October 10, 2021

Nutraceutical giants’ partnerships inject life back into industry at Vitafoods

Life sciences

Some of industry’s biggest players are joining forces to bring cost-effective yet scientifically backed offerings to the nutraceuticals market. Co-creation is reinvigorating supplement innovation, pairing together companies’ diverse expertise, sales networks and clinical trial investments.

October 10, 2021

Pilot launch complete: GlaxoSmithKline’s malaria shot scores WHO backing for wider rollout in Africa

Life sciences

GlaxoSmithKline has spent many years developing and testing its world-first malaria vaccine, but even after a positive recommendation from European regulators in 2015, the shot still isn’t widely deployed. That’s set to change with the World Health Organization’s (WHO’s) blessing for the vaccine.

October 10, 2021

Henrietta Lacks’ estate sues Thermo Fisher for continued sale of HeLa cells without family consent

Life sciences

A sample of Henrietta Lacks’ tissue was taken from her cervix without her consent while she was undergoing cancer treatment at Johns Hopkins Hospital in 1951. Her cells have subsequently been used to develop the polio vaccine, HPV vaccines and gene-mapping techniques and continue to be sold for research purposes by Thermo Fisher Scientific.

Send this to a friend